Leerink Swann reissued their outperform rating on shares of Flamel Technologies SA (NASDAQ:FLML) in a report published on Tuesday morning. Leerink Swann currently has a $16.00 target price on the stock.
Separately, Zacks Investment Research raised Flamel Technologies SA from a sell rating to a hold rating in a research note on Tuesday, July 12th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Flamel Technologies SA currently has an average rating of Buy and a consensus target price of $18.63.
Shares of Flamel Technologies SA (NASDAQ:FLML) opened at 13.00 on Tuesday. Flamel Technologies SA has a 12 month low of $7.56 and a 12 month high of $19.78. The company has a market cap of $536.13 million, a P/E ratio of 31.48 and a beta of 1.42. The stock’s 50 day moving average price is $13.75 and its 200-day moving average price is $11.75.
Flamel Technologies SA (NASDAQ:FLML) last released its quarterly earnings data on Monday, August 8th. The company reported ($0.02) earnings per share for the quarter, missing analysts’ consensus estimates of $0.06 by $0.08. The business earned $38.90 million during the quarter, compared to the consensus estimate of $32.80 million. Flamel Technologies SA had a return on equity of 25.19% and a net margin of 12.11%. The business’s revenue was down 20.0% on a year-over-year basis. During the same period last year, the company earned $0.34 EPS. Equities research analysts expect that Flamel Technologies SA will post ($1.08) earnings per share for the current year.
In other news, CEO Michael S. Anderson purchased 5,000 shares of the company’s stock in a transaction that occurred on Monday, August 22nd. The stock was bought at an average cost of $14.30 per share, with a total value of $71,500.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Craig R. Stapleton purchased 20,000 shares of the company’s stock in a transaction that occurred on Friday, August 26th. The shares were purchased at an average cost of $13.76 per share, with a total value of $275,200.00. Following the completion of the purchase, the director now owns 509,678 shares of the company’s stock, valued at approximately $7,013,169.28. The disclosure for this purchase can be found here. Corporate insiders own 4.45% of the company’s stock.
A number of institutional investors have recently made changes to their positions in FLML. DekaBank Deutsche Girozentrale purchased a new position in shares of Flamel Technologies SA during the second quarter worth approximately $210,000. Quantitative Systematic Strategies LLC purchased a new position in shares of Flamel Technologies SA during the second quarter worth approximately $261,000. Smith Asset Management Group LP purchased a new position in shares of Flamel Technologies SA during the second quarter worth approximately $320,000. ProShare Advisors LLC raised its position in shares of Flamel Technologies SA by 0.6% in the second quarter. ProShare Advisors LLC now owns 29,957 shares of the company’s stock worth $322,000 after buying an additional 171 shares during the last quarter. Finally, State Street Corp raised its position in shares of Flamel Technologies SA by 2.6% in the second quarter. State Street Corp now owns 30,682 shares of the company’s stock worth $330,000 after buying an additional 787 shares during the last quarter. 70.33% of the stock is owned by institutional investors.
About Flamel Technologies SA
Flamel Technologies SA is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its polymer based technology. The Company has a balanced business model consisting of an Unapproved Marketed Drugs (UMDs) business with over two approved products in the United States, Bloxiverz (neostigmine methylsulfate injection) and Vazculep (phenylephrine hydrochloride injection) that are marketed; a branded pediatric business, and a branded business, focusing on the development of products utilizing Flamel’s drug delivery platforms.
Receive News & Ratings for Flamel Technologies SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flamel Technologies SA and related companies with MarketBeat.com's FREE daily email newsletter.